Association Between Ulcerative Colitis and Pulmonary Embolism
Magnitude of Risk
- Patients with ulcerative colitis have at least a 2-fold increased risk of venous thromboembolism (VTE), including pulmonary embolism, compared to the general population, with the highest risk occurring during active disease and hospitalization 1, 2
- UC patients face a 2.0 to 2.85-fold increased risk of VTE compared to healthy controls, with pulmonary embolism being one of the most common manifestations alongside deep vein thrombosis 2, 3
- The risk of thrombosis-related mortality is doubled in UC patients compared to controls 1, 3, 4
- Among hospitalized IBD patients undergoing surgery, VTE occurs in 3.3% of UC patients 2
- VTE-associated mortality is significantly elevated: 37.4 per 1,000 hospitalizations for UC versus 9.9 per 1,000 in non-UC patients (p<0.0001) 2
Pathophysiology and Risk Factors
- The majority of VTE events occur during active disease phases, as inflammatory activity drives hemostatic alterations that promote thrombosis 1, 3, 4
- Hospitalization independently increases VTE risk 8-fold in UC patients 1, 5, 4
- Most VTE events occur in outpatients who have risk factors such as recent hospitalization, surgery, or active disease 2
Clinical Manifestations
- Deep vein thrombosis and pulmonary embolism are the most common thromboembolic manifestations 1, 3, 4
- VTE is associated with longer hospitalizations (11.7 vs 6.1 days in non-VTE patients) 2
- Recurrent VTE is increased in UC patients: 33.4% recur within 5 years after unprovoked first VTE versus 21.7% in non-IBD patients (relative risk 2.5, p=0.001) 2
Prevention Strategies
- All hospitalized UC patients should receive thromboprophylaxis, particularly those with acute severe disease 1, 5, 2, 6, 4
- Prophylaxis with low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux is recommended for all hospitalized UC patients 1, 5, 2, 6, 4
- Both mechanical thromboprophylaxis and pharmacological prophylaxis should be considered in at-risk patients 1, 3, 4
- The British Society of Gastroenterology (2025) explicitly states that patients with acute severe UC should receive prophylactic LMWH despite bleeding risk 6
Treatment of Established PE
- Treatment should follow standard antithrombotic therapy guidelines and is independent of the UC diagnosis 1, 5, 3, 4
- Anticoagulation should continue for at least 3 months using LMWH, UFH, or fondaparinux initially, followed by vitamin K antagonists 1, 5, 3, 4
- Long-term anticoagulation should be considered for patients with a second episode of unprovoked VTE 1, 5, 3, 4
Clinical Implications
- The threshold for investigating VTE should be lower in UC patients, especially those with active disease 2
- Diagnosis follows standard protocols: ultrasound for DVT, ventilation-perfusion scan or CT pulmonary angiography for PE 1, 2, 3, 4
- VTE often presents with non-specific symptoms and should be considered in all UC patients with compatible clinical features 2